Patients' priorities around drug-resistant tuberculosis treatment: A multi-national qualitative study from Mongolia, South Africa and Georgia.

Journal: Global public health

Volume: 18

Issue: 1

Year of Publication: 2023

Affiliated Institutions:  MRC Clinical Trials Unit at UCL, UCL, London, UK. Mongolian TB Coalition, Ulaanbaatar, Mongolia. THINK: TB and HIV Investigative Network, Durban, South Africa. TB Clinical Research Unit, National Centre for Tuberculosis and Lung Diseases, Tbilisi, Georgia. TB Research and Surveillance Department, National Center for Communicable Diseases, Ulaanbaatar, Mongolia. Davit Tvildiani Medical University, Tbilisi, Georgia. Institute for Global Health, UCL, London, UK.

Abstract summary 

We conducted qualitative research exploring the treatment experience of people with DR-TB. We held nine focus group discussions with 57 adults undergoing/recently completed treatment for DR-TB in Georgia, Mongolia and South Africa. Translated transcripts were analysed using thematic analysis. We identified three higher order themes: (1) Treatment experience and the role of good relationships with healthcare providers: Treatment duration, pill burden and side-effects were challenging aspects of treatment. Side-effects/symptoms that were visible signs of illness were particularly troubling. Good relations with clinical staff helped combat fear and uncertainty regarding treatment. (2) Mental distress and opportunities for wellbeing: The shame, stigma and isolation people experienced as a result of their DR-TB diagnosis was an important cause of mental distress. No longer being infectious enabled people to resume work and socialising. Positive emotions emerged with good treatment outcomes. (3) Fear and worry along the treatment journey: Participants expressed fears about TB: infecting others; whether they would be able to endure treatment; side-effects; health consequences of treatment. Worries mostly disappeared with successful treatment. Alongside measuring side-effects, time to culture conversion and cure rates, future trials of DR-TB treatments should capture how quickly visible symptoms resolve, quality of life measures, and mental health outcomes.

Authors & Co-authors:  South Annabelle A Dhesi Parveen P Tweed Conor D CD Tsogt Bazarragchaa B Staples Suzanne S Tukvadze Nestani N Dorj Gantsetseg G Zaca Sindisiwe S Sanikidze Ekaterine E Purev Nasanjargal N Esmail Hanif H Burgess Rochelle R

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  12
Identifiers
Doi : 10.1080/17441692.2023.2234450
SSN : 1744-1706
Study Population
Male,Female
Mesh Terms
Adult
Other Terms
Drug-resistant tuberculosis;Qualitative research;Treatment experience
Study Design
Cross Sectional Study
Study Approach
Qualitative
Country of Study
South Africa
Publication Country
England